IO Biotech
IOBT
IOBT was delisted on the 6th of April, 2026.
18 hedge funds and large institutions have $59.6M invested in IO Biotech in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 4 closing their positions.
43% more capital invested
Capital invested by funds: $41.7M → $59.6M (+$17.9M)
3.06% more ownership
Funds ownership: 45.03% → 48.09% (+3.1%)
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
5% less funds holding
Funds holding: 19 → 18 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$5.36M |
| 2 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$1.18M |
| 3 |
Renaissance Technologies
New York
|
+$76.9K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$61.8K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$15.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$2.84M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.18M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$369K |
| 4 |
AC
Armistice Capital
New York
|
-$267K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$29.3K |
IOBT Hedge Fund Activity: Q4 2023 in Review
18 of the 6,865 institutional investors tracked by Wall St. Rank reported a position in IO Biotech (IOBT) for Q4 2023, worth a combined $59.6M — up 43% from $41.7M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of IOBT and 3 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 4 added.
The largest buyer was Morgan Stanley, adding an estimated $5.36M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $2.84M sold.
- 18 institutional investors held IO Biotech (IOBT) as of Q4 2023, down from 19 in Q3 2023.
- Funds reported $59.6M of IO Biotech stock for Q4 2023, up 43% quarter-over-quarter.
- 3 funds opened new IO Biotech positions in Q4 2023 and 4 closed out, a net change of -1 holder.
- The largest IO Biotech buyer in Q4 2023 was Morgan Stanley, an estimated $5.36M added.
- The largest IO Biotech seller in Q4 2023 was Avoro Capital Advisors, an estimated $2.84M sold.
Based on aggregated 13F filings for Q4 2023.